305 related articles for article (PubMed ID: 26097599)
21. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
Shi ZH; Shi GY; Liu LG
Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
[TBL] [Abstract][Full Text] [Related]
22. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
Gao H; Ge RC; Liu HY; Wang Y; Yan S
Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
[TBL] [Abstract][Full Text] [Related]
23. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.
Wang MJ; Zhu Y; Guo XJ; Tian ZZ
Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406
[TBL] [Abstract][Full Text] [Related]
24. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.
Zhao F; Shang Y; Zeng C; Gao D; Li K
Int J Clin Exp Pathol; 2015; 8(9):11579-86. PubMed ID: 26617894
[TBL] [Abstract][Full Text] [Related]
25. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
[TBL] [Abstract][Full Text] [Related]
27. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer.
Chen ZH; Wang L; Luo LP
Genet Mol Res; 2014 Sep; 13(3):7484-91. PubMed ID: 25222248
[TBL] [Abstract][Full Text] [Related]
28. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
[TBL] [Abstract][Full Text] [Related]
29. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
30. Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA.
Lu B; Li J; Gao Q; Yu W; Yang Q; Li X
Gene; 2014 May; 542(1):64-8. PubMed ID: 24582975
[TBL] [Abstract][Full Text] [Related]
31. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
32. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
[TBL] [Abstract][Full Text] [Related]
33. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Valdivia-Bautista J; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics J; 2019 Apr; 19(2):164-177. PubMed ID: 29662106
[TBL] [Abstract][Full Text] [Related]
35. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.
Li J; Zuo X; Lv X; Kong F; Xu W; Yang S
Tumour Biol; 2014 Aug; 35(8):7569-74. PubMed ID: 24793015
[TBL] [Abstract][Full Text] [Related]
36. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
[TBL] [Abstract][Full Text] [Related]
37. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
39. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
40. Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer.
He MG; Zheng K; Tan D; Wang ZX
Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27051038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
